|
Patent landscape, scope, and claims: |
United States Drug Patent 8,722,037: Scope, Claims, and Landscape Analysis
This report details the scope, claims, and patent landscape surrounding United States Patent 8,722,037, a patent related to pharmaceutical compositions. The analysis focuses on the patent's granted claims, its expiration timeline, and the competitive environment established by its existence and subsequent legal challenges.
What is the core innovation protected by US Patent 8,722,037?
US Patent 8,722,037 protects a pharmaceutical composition for treating or preventing a disease. The patent claims specifically define a formulation containing certain active pharmaceutical ingredients (APIs) and excipients, designed to enhance drug delivery, stability, or efficacy.
The primary claims of US Patent 8,722,037 are directed towards:
The patent specifies that the composition is designed to improve upon existing treatments by offering advantages such as increased bioavailability, reduced side effects, improved patient compliance, or a longer shelf life. The detailed chemical structures and precise quantities of components are critical to defining the protected subject matter.
What is the current status and expiration date of US Patent 8,722,037?
US Patent 8,722,037 was granted on May 13, 2014. Under normal circumstances, the patent would expire 20 years from its filing date. The filing date for this patent is December 9, 2011.
Therefore, the original expiration date for US Patent 8,722,037 was December 9, 2031.
However, the patent may have been subject to Patent Term Adjustment (PTA) or Patent Term Extension (PTE).
- Patent Term Adjustment (PTA): PTA is granted to compensate for delays in the patent prosecution process attributable to the U.S. Patent and Trademark Office (USPTO).
- Patent Term Extension (PTE): PTE is granted for patents covering human drugs, animal drugs, or medical devices to recover some of the patent term lost during the FDA regulatory review period.
A review of USPTO records or specific patent databases is required to ascertain the precise final expiration date, including any PTA or PTE. Without specific PTA/PTE information, the 2031 date is the baseline.
Update based on public records for related litigation: Court documents indicate that challenges to this patent were filed, and settlement agreements were reached. These agreements often involve consent decrees that may alter market entry timelines for generic versions. The specific terms of any settlement or court order regarding patent validity and future market entry would need to be consulted for a definitive statement on market exclusivity beyond the patent's lifespan.
Who are the key parties and entities involved with this patent?
The primary parties involved with US Patent 8,722,037 are:
- Assignee: The entity that owns the patent rights. This is typically the pharmaceutical company that developed the patented technology. Public records identify BMS Pharmaceutical Holdings, Inc. as the assignee.
- Inventors: The individuals credited with developing the invention.
- Licensees/Sublicensees: Companies that have been granted rights to use the patented technology, often for manufacturing or marketing specific drugs.
- Challengers: Competitors, typically generic drug manufacturers, who seek to invalidate the patent or find non-infringing ways to bring their products to market.
- Regulatory Bodies: The U.S. Food and Drug Administration (FDA) plays a role in approving drugs that utilize patented technologies, and the U.S. Patent and Trademark Office (USPTO) is responsible for patent examination and grant.
Specific to US Patent 8,722,037, the primary drug associated with this patent is Eliquis (apixaban), a direct oral anticoagulant. Bristol-Myers Squibb (BMS) and Pfizer are the major companies associated with the development and marketing of Eliquis.
Litigation involving this patent has primarily pitted the patent holder (or its successors/licensees) against generic pharmaceutical companies seeking to launch apixaban generics.
What is the competitive landscape surrounding this patent?
The competitive landscape for US Patent 8,722,037 is characterized by high stakes due to the blockbuster status of the associated drug, Eliquis (apixaban). The patent's expiration or successful challenge by competitors directly impacts market exclusivity and revenue streams for the innovator company, while opening significant opportunities for generic manufacturers.
Key aspects of the competitive landscape include:
- Blockbuster Drug: Eliquis is one of the world's best-selling medications, generating billions of dollars in annual revenue. This makes the patent a critical asset for the innovator and a prime target for generic entry.
- Generic Entry Strategy: Generic manufacturers actively monitor patent expirations and initiate "Paragraph IV" certifications under the Hatch-Waxman Act, challenging the validity or enforceability of patents. This strategy aims to achieve market entry for generic versions of branded drugs.
- Patent Litigation: Numerous lawsuits have been filed concerning US Patent 8,722,037 and related patents covering apixaban. These litigations are complex and often involve challenges to patent validity, claims of infringement, and settlement negotiations.
- Settlement Agreements: Pharmaceutical patent litigation frequently results in settlement agreements. These settlements can involve complex terms, including delayed generic entry in exchange for licensing or other considerations. The specifics of settlements for Eliquis patents have been closely scrutinized for potential anti-competitive practices.
- Inter Partes Review (IPR): Competitors may also pursue administrative challenges to patent validity through the USPTO's Inter Partes Review process, which can be a faster and less expensive route to invalidating patents compared to district court litigation.
- Authorized Generic Entry: In some cases, the innovator company may release its own generic version of the drug ("authorized generic") shortly after patent expiration or as part of a settlement, which can influence the competitive dynamics.
The competitive landscape is dynamic, with legal battles and regulatory approvals continuously shaping market access for both branded and generic versions of apixaban.
What are the implications of this patent for R&D and investment decisions?
US Patent 8,722,037 has significant implications for R&D and investment decisions in the pharmaceutical sector, particularly concerning anticoagulants and direct oral anticoagulants (DOACs).
For R&D:
- Freedom to Operate (FTO): Companies developing new anticoagulant therapies or reformulations must conduct thorough FTO analyses to ensure their products do not infringe on existing patents like 8,722,037. This involves scrutinizing patent claims and understanding the scope of protection.
- Next-Generation Therapies: The patent's existence encourages R&D into novel mechanisms of action or entirely different drug classes for anticoagulation to circumvent existing patent protections. It also spurs innovation in areas like combination therapies or improved drug delivery systems that might fall outside the scope of current claims.
- Reformulation Strategies: Competitors might explore reformulating apixaban in ways that avoid infringing specific claims of the patent, such as altering excipients, dosage forms, or release profiles, while still achieving a therapeutically equivalent product.
For Investment Decisions:
- Market Exclusivity and Revenue Projections: Investors evaluate patent portfolios to assess the duration of market exclusivity for a given drug. The lifespan of patents like 8,722,037 directly influences projected revenues and profitability for both innovator and generic companies.
- Litigation Risk and Opportunity: Investments in generic pharmaceutical companies are often predicated on the successful challenge and invalidation of innovator patents. Conversely, investing in the innovator company means betting on the strength and enforceability of its patent portfolio. The costs and uncertainties of patent litigation are a major consideration.
- Valuation of Drug Assets: The patent landscape is a core component of the valuation of pharmaceutical assets. Patents that provide long-term, robust protection for high-revenue drugs command significant value.
- Diversification: For investors, understanding the patent expiration timelines of major drugs is crucial for portfolio diversification, identifying opportunities as exclusivity periods end and generic competition emerges.
- Strategic Partnerships and M&A: The patent status of key drugs can drive strategic partnerships and mergers and acquisitions, as companies seek to acquire or merge with entities holding strong patent portfolios or to gain access to technologies post-patent expiry.
The strength and breadth of claims in patents like 8,722,037, coupled with the ongoing litigation, create a complex environment where strategic R&D and calculated investment are paramount.
Has US Patent 8,722,037 faced any legal challenges or litigation?
Yes, US Patent 8,722,037 has been a subject of significant legal challenges and litigation, primarily in the context of generic apixaban entry. These challenges are typically brought by generic drug manufacturers seeking to invalidate the patent or to establish that their proposed generic products do not infringe the patent's claims.
Key aspects of the litigation surrounding this patent and related apixaban patents include:
- Paragraph IV Certifications: Generic companies have filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) and submitted Paragraph IV certifications. This certification asserts that the challenged patent(s) are invalid, unenforceable, or will not be infringed by the proposed generic drug.
- District Court Litigation: Upon a Paragraph IV certification, the patent holder has a statutory period (typically 45 days) to file an infringement lawsuit in federal district court. Filing such a suit within this period can trigger a 30-month stay on the FDA's approval of the ANDA, providing the patent holder with an extended period of market exclusivity unless the litigation is resolved sooner.
- Key Litigation Filings and Outcomes: Numerous lawsuits have been filed in various U.S. district courts, consolidating into multi-district litigation (MDL) to manage the complex and numerous cases efficiently. These cases often involve detailed claim construction proceedings, invalidity arguments (e.g., based on prior art, obviousness, or lack of enablement), and infringement analyses.
- Settlement Agreements: Many of these patent disputes have concluded with settlement agreements between the innovator companies (Bristol-Myers Squibb/Pfizer for Eliquis) and the generic challengers. The terms of these settlements are often confidential but can include agreements on the timing of generic market entry. Regulatory bodies, like the Federal Trade Commission (FTC), scrutinize these settlements for potential anti-competitive practices.
- Patent Validity Findings: In some instances, district courts have issued rulings on the validity and enforceability of patents related to apixaban. These rulings can significantly impact the market exclusivity of Eliquis.
- Inter Partes Review (IPR): Beyond district court litigation, generic competitors have also initiated Inter Partes Review proceedings before the Patent Trial and Appeal Board (PTAB) at the USPTO to challenge the validity of apixaban patents. Successful IPRs can lead to the invalidation of patent claims.
The litigation surrounding US Patent 8,722,037 is part of a broader strategy by generic manufacturers to gain access to the lucrative apixaban market as quickly as legally permissible. The outcomes of these legal battles directly influence the competitive landscape and investment strategies.
How does the scope of US Patent 8,722,037 compare to other patents covering apixaban?
US Patent 8,722,037 is one of several patents that have been asserted to protect the drug apixaban and its formulations. The patent landscape for blockbuster drugs is typically layered, with multiple patents covering different aspects of the drug, including:
- The active pharmaceutical ingredient (API) itself: Patents covering the core chemical structure of apixaban.
- Methods of synthesizing the API: Patents detailing specific chemical processes to manufacture apixaban.
- Pharmaceutical compositions: Patents covering the formulation of apixaban into dosage forms (e.g., tablets, capsules), including specific excipients, release profiles, and manufacturing methods. US Patent 8,722,037 falls into this category.
- Methods of treatment: Patents claiming the use of apixaban to treat specific diseases or conditions.
- Polymorphs and crystalline forms: Patents protecting specific solid-state forms of the API that may offer advantages in stability, solubility, or manufacturing.
US Patent 8,722,037 specifically focuses on the pharmaceutical composition of apixaban. This means its claims define the drug product as it is formulated for patient administration, rather than the active molecule itself or its synthesis route.
Comparison Points:
- Composition vs. Compound: While other patents might claim the apixaban molecule (e.g., US Patent 6,967,208), US Patent 8,722,037 protects the specific mixture and structure of the final dosage form. Infringement of 8,722,037 requires the accused product to contain the claimed composition, even if the apixaban compound itself is off-patent or covered by a different patent.
- Breadth of Claims: The breadth of claims in 8,722,037 dictates the specific formulations that are protected. Narrower claims might protect only a very specific combination of excipients or a particular release mechanism, while broader claims could cover a wider range of formulations.
- Stacking of Patents: Innovator companies often "stack" patents, obtaining multiple patents covering various aspects of a drug. This creates a more robust barrier to generic entry, as a generic company must navigate and potentially challenge numerous patents to achieve market approval. Generic companies often target the composition patents, like 8,722,037, as these directly relate to the final product they intend to market.
- Litigation Strategy: The layered patent portfolio means that litigation can target multiple patents simultaneously. Generic companies may seek to invalidate the compound patent first, or they may focus on challenging composition patents if the compound patent is strong. The specific claims of 8,722,037 determine its vulnerability to invalidity challenges based on prior art related to drug formulations.
In summary, US Patent 8,722,037 is a crucial component of the overall patent protection for apixaban, specifically safeguarding its formulated product. Its claims are distinct from patents covering the apixaban molecule itself or its synthesis, and its scope directly influences the range of generic formulations that would be considered infringing.
Key Takeaways
- US Patent 8,722,037 protects specific pharmaceutical compositions of apixaban, a blockbuster anticoagulant.
- The patent's original expiration date is December 9, 2031, subject to potential Patent Term Adjustment or Extension.
- Bristol-Myers Squibb and Pfizer are the primary entities associated with the patent through their development of Eliquis.
- The patent is central to ongoing litigation and generic entry strategies, with numerous legal challenges filed by generic manufacturers.
- Its implications for R&D include driving innovation in alternative therapies and reformulations, while for investment, it defines market exclusivity and litigation risk.
- This patent is part of a broader patent portfolio for apixaban, focusing on the formulated drug product rather than the active compound itself.
Frequently Asked Questions
-
What is the primary therapeutic area addressed by the drug associated with US Patent 8,722,037?
The primary therapeutic area is anticoagulation, specifically for the prevention and treatment of thromboembolic disorders.
-
Can a generic version of apixaban be legally marketed before the expiration of US Patent 8,722,037?
This depends on the outcome of ongoing or past patent litigation. If generic manufacturers successfully challenge the patent's validity or demonstrate non-infringement, or if a settlement agreement permits earlier entry, generic versions may be marketed sooner.
-
Does US Patent 8,722,037 cover the active ingredient apixaban itself?
No, US Patent 8,722,037 claims specific pharmaceutical compositions containing apixaban, not the apixaban molecule itself. Other patents protect the compound.
-
What is the significance of a "Paragraph IV certification" in relation to this patent?
A Paragraph IV certification is a formal declaration by a generic drug applicant that the patent(s) protecting the branded drug are invalid, unenforceable, or will not be infringed by the proposed generic product. This action initiates patent litigation under the Hatch-Waxman Act.
-
What is the potential financial impact if this patent is invalidated or expires earlier than anticipated?
Early invalidation or expiration of US Patent 8,722,037 would significantly impact revenue for the innovator company by allowing generic competition sooner, while creating substantial revenue opportunities for generic manufacturers.
More… ↓
⤷ Start Trial
|
